Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Julphar
Argus Health
Covington
Mallinckrodt
Chubb
UBS
AstraZeneca
McKinsey
Boehringer Ingelheim

Generated: October 23, 2017

DrugPatentWatch Database Preview

Allergan Company Profile

« Back to Dashboard

What is the competitive landscape for ALLERGAN, and when can generic versions of ALLERGAN drugs launch?

ALLERGAN has one hundred and one approved drugs.

There are one hundred and twenty US patents protecting ALLERGAN drugs on ALLERGAN drugs in the past three years.

There are eight hundred and ten patent family members on ALLERGAN drugs in forty-four countries and ninety-one supplementary protection certificates in twelve countries.

Summary for Applicant: Allergan

International Patents:810
US Patents:120
Tradenames:86
Ingredients:64
NDAs:101
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan Herbert
TEMARIL
trimeprazine tartrate
CAPSULE, EXTENDED RELEASE;ORAL011316-004Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Allergan
OZURDEX
dexamethasone
IMPLANT;INTRAVITREAL022315-001Jun 17, 2009RXYesYes► Subscribe► Subscribe► Subscribe
Allergan Sales Llc
KADIAN
morphine sulfate
CAPSULE, EXTENDED RELEASE;ORAL020616-004Mar 9, 2001ABRXYesNo► Subscribe► Subscribe► Subscribe
Allergan
CHLOROPTIC
chloramphenicol
SOLUTION/DROPS;OPHTHALMIC050091-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Allergan Holdings
VIBERZI
eluxadoline
TABLET;ORAL206940-001May 27, 2015RXYesNo► Subscribe► Subscribe ► Subscribe
Allergan Sales Llc
OXYTROL FOR WOMEN
oxybutynin
FILM, EXTENDED RELEASE;TRANSDERMAL202211-001Jan 25, 2013OTCYesYes► Subscribe► SubscribeY ► Subscribe
Allergan
LATISSE
bimatoprost
SOLUTION/DROPS;TOPICAL022369-001Dec 24, 2008ATRXYesYes► Subscribe► Subscribe ► Subscribe
Allergan Holdings
VIBERZI
eluxadoline
TABLET;ORAL206940-001May 27, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Allergan
OZURDEX
dexamethasone
IMPLANT;INTRAVITREAL022315-001Jun 17, 2009RXYesYes► Subscribe► Subscribe ► Subscribe
Allergan
SANCTURA XR
trospium chloride
CAPSULE, EXTENDED RELEASE;ORAL022103-001Aug 3, 2007DISCNYesNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Allergan

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan Sales Llc
KADIAN
morphine sulfate
CAPSULE, EXTENDED RELEASE;ORAL020616-007Feb 27, 2007► Subscribe► Subscribe
Allergan Sales Llc
ALORA
estradiol
FILM, EXTENDED RELEASE;TRANSDERMAL020655-004Apr 5, 2002► Subscribe► Subscribe
Allergan Sales Llc
DILACOR XR
diltiazem hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020092-003May 29, 1992► Subscribe► Subscribe
Allergan
OCUFLOX
ofloxacin
SOLUTION/DROPS;OPHTHALMIC019921-001Jul 30, 1993► Subscribe► Subscribe
Allergan Sales Llc
KADIAN
morphine sulfate
CAPSULE, EXTENDED RELEASE;ORAL020616-008Apr 20, 2007► Subscribe► Subscribe
Allergan Sales Llc
ANDRODERM
testosterone
FILM, EXTENDED RELEASE;TRANSDERMAL020489-002May 2, 1997► Subscribe► Subscribe
Allergan Sales Llc
RAPAFLO
silodosin
CAPSULE;ORAL022206-002Oct 8, 2008► Subscribe► Subscribe
Allergan Sales Llc
KADIAN
morphine sulfate
CAPSULE, EXTENDED RELEASE;ORAL020616-006Oct 27, 2006► Subscribe► Subscribe
Allergan Sales Llc
CONDYLOX
podofilox
GEL;TOPICAL020529-001Mar 13, 1997► Subscribe► Subscribe
Allergan
OPTICROM
cromolyn sodium
SOLUTION/DROPS;OPHTHALMIC018155-001Oct 3, 1984► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for ALLERGAN drugs

Drugname Dosage Strength Tradename Submissiondate
dapsone
Gel7.5%
ACZONE
2/13/2017
alcaftadine
Ophthalmic Solution0.25%
LASTACAFT
7/30/2014
oxybutynin chloride
Gel10%
GELNIQUE
6/19/2014
milnacipran hydrochloride
Tablets12.5 mg, 25 mg, 50 mg, and 100 mg
SAVELLA
1/14/2013
silodosin
Capsules4 mg and 8 mg
RAPAFLO
10/9/2012
ketorolac tromethamine
Opthalmic Solution0.45%
ACUVAIL
8/24/2011
ketorolac tromethamine
Opthalmic Solution0.45%
ACUVAIL
8/23/2011
bimatoprost
Ophthalmic Solution0.01%
LUMIGAN
4/5/2011
gatifloxacin
Ophthalmic Solution0.5%
ZYMAXID
12/7/2010
bimatopros
Topical Solution0.03%
LATISSE
5/3/2010
trospium chloride
Extended-release Capsules60 mg
SANCTURA XR
3/2/2009
bimatoprost
Ophthalmic Solution0.03%
LUMIGAN
12/22/2008
brimonidine tartrate and timolol maleate
Ophthalmic Solution0.2%/0.5%
COMBIGAN
11/21/2008
epinastine hydrochloride
Ophthalmic Solution0.05%
ELESTAT
10/14/2008
oxybutynin
Transdermal System Extended-re3.9 mg/24 hrs
OXYTROL
8/19/2008
gatifloxacin
Ophthalmic Solution0.30%
ZYMAR
7/19/2007
brimonidine tartrate
Ophthalmic Solution0.10%
ALPHAGAN P
12/20/2006
brimonidine tartrate
Ophthalmic Solution0.15%
ALPHAGAN P
11/3/2006
ketorolac tromethamine
Ophthalmic Solution0.40%
ACULAR LS
1/28/2005

Premature patent expirations for ALLERGAN

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
► Subscribe ► Subscribe

Non-Orange Book Patents for Allergan

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,994,206Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-- 1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid► Subscribe
7,214,381Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels► Subscribe
8,298,518Method of enhancing hair growth► Subscribe
8,828,446Method for reducing transplant rejection in the eye and intraocular implants for use therefor► Subscribe
7,470,433Formulations for transdermal or transmucosal application► Subscribe
7,915,246Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain► Subscribe
8,926,953Method of enhancing hair growth► Subscribe
7,387,788Pharmaceutical compositions of nicotine and methods of use thereof► Subscribe
8,618,064Methods of providing therapeutic effects using cyclosporin components► Subscribe
8,652,491Transdermal compositions for anticholinergic agents► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Allergan Drugs

Country Document Number Estimated Expiration
New Zealand522610► Subscribe
European Patent Office1680110► Subscribe
Canada2429998► Subscribe
Norway20074390► Subscribe
Germany60127277► Subscribe
EcuadorSP109863► Subscribe
Spain2593113► Subscribe
South Korea20040100844► Subscribe
Australia7316601► Subscribe
China1438861► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Allergan Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00552Netherlands► SubscribePRODUCT NAME: VOOR GEBRUIK IN EEN WERKWIJZE VOOR DE BEHANDELING VAN MACULAIR OEDEEM; REG. NO/DATE: EU/1/10/638/001 20100727
2011 00026Denmark► SubscribePRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216
2017000010Germany► SubscribePRODUCT NAME: ELUXADOLIN; REGISTRATION NO/DATE: EU/1/16/1126 20160919
C0020France► SubscribePRODUCT NAME: COMBINAISON COMRENANT L’ALISKIREN SOUS FORME DE BAE LIBRE OU UN SEL DE CELUI-CI PHARMACEUTIQUEMENT ACCEPTABLE, ET L’HYDROCHLOROTHIAZIDE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE IN FRANCE: EU/1/08/491/001 DU 20090116; REGISTRATION NO/DATE AT EEC: 58935 01-04 DU 20081028
C/GB97/085United Kingdom► SubscribePRODUCT NAME: LEVOFLOXACIN, OPTIONALLY IN THE FORM OF A HEMIHYDRATE; REGISTERED: UK 13402/0011 19970606; UK 13402/0012 19970606; UK 13402/0013 19970606
156Luxembourg► SubscribePRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211
C0003Belgium► SubscribePRODUCT NAME: ESTRADIOL AND NORETHISTERONE; FIRST REGISTRATION NO/DATE: 403 IS 106 F3 19980928; FIRST REGISTRATION: SE 14007 19980306
/2001Austria► SubscribePRODUCT NAME: ALITRETINOIN; REGISTRATION NO/DATE: EU/1/00/149/001 20001011
923Luxembourg► SubscribePRODUCT NAME: UNE SOLUTION D'IRRIGATION OCULAIRE COMPRENANT DE LA PHENYLEPHRINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI ET DU KETOROLAC OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; FIRST REGISTRATION: 20150730
/2015Austria► SubscribePRODUCT NAME: PHENYLEPHRIN, ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, UND KETOROLAC, ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1018 (MITTEILUNG) 20150730
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
UBS
US Department of Justice
Chubb
QuintilesIMS
Colorcon
Federal Trade Commission
Dow
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot